Clinical Trials Logo

Filter by:
NCT ID: NCT04769050 Recruiting - Breast Cancer Clinical Trials

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Start date: February 18, 2021
Phase:
Study type: Observational

Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment

NCT ID: NCT04768868 Recruiting - Clinical trials for Advanced Solid Tumors

The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

WEE1
Start date: February 25, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors

NCT ID: NCT04768816 Recruiting - Clinical trials for Safety Issues;Effect of Drugs

Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder

Start date: July 1, 2019
Phase: Phase 1
Study type: Interventional

To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of autism spectrum disorder.

NCT ID: NCT04768699 Recruiting - Clinical trials for Hemophilia A With Inhibitor

Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.

NCT ID: NCT04768491 Recruiting - NSCLC Stage IV Clinical Trials

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Start date: September 1, 2020
Phase:
Study type: Observational

This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.

NCT ID: NCT04768465 Recruiting - Myasthenia Gravis Clinical Trials

Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

This study is designed to evaluate the effectiveness and safety of tacrolimus combined with low-dose prednisone in the management of myasthenia gravis patients, compared to tacrolimus as initial immune monotherapy.

NCT ID: NCT04768270 Recruiting - Ovarian Cancer Clinical Trials

The Culture of Ovarian Cancer Organoids and Drug Screening

Start date: April 12, 2022
Phase:
Study type: Observational [Patient Registry]

The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.

NCT ID: NCT04767828 Recruiting - TTP Clinical Trials

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

Start date: May 1, 2020
Phase: Phase 4
Study type: Interventional

The aim of this study was to evaluate the progression time and efficacy of brain tumors in patients with brain metastases from HER2-positive breast cancer treated with Pyrrolidine and Capecitabine combined with brain radiotherapy.

NCT ID: NCT04767620 Recruiting - Clinical trials for Mammary Gland Hyperplasia

Clinical Trial of Ruxian Zengsheng No. 1 Decoction

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

A prospective, open, randomized, controlled phase II clinical study is planned to clarify the efficacy and related adverse reactions of Mammary Glandular Hyperplasia No. 1 Decoction in the treatment of liver-qi stagnation type breast hyperplasia, relieve the pain of patients with breast hyperplasia, and improve the quality of life of patients.

NCT ID: NCT04767295 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal squamous cell carcinoma